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The ongoing merge between engineering and biology has contributed to the emerging ﬁeld of syn-
thetic biology. The deﬁning features of this new discipline are abstraction and standardisation of
biological parts, decoupling between parts to prevent undesired cross-talking, and the application
of quantitative modelling of synthetic genetic circuits in order to guide their design.
Most of the efforts in the ﬁeld of synthetic biology in the last decade have been devoted to the
design and development of functional gene circuits in prokaryotes and unicellular eukaryotes.
Researchers have used synthetic biology not only to engineer new functions in the cell, but also
to build simpler models of endogenous gene regulatory networks to gain knowledge of the ‘‘rules’’
governing their wiring diagram.
However, the need for innovative approaches to study and modify complex signalling and regula-
tory networks in mammalian cells and multicellular organisms has prompted advances of synthetic
biology also in these species, thus contributing to develop innovative ways to tackle human diseases.
In this work, we will review the latest progress in synthetic biology and the most signiﬁcant devel-
opments achieved so far, both in unicellular and multicellular organisms, with emphasis on human
health.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
The possibility of modifying, or creating de novo, cells and
organisms with the aim of solving the open challenges in human
health and in biotechnology will open up completely new avenues
of research and applications, as well as safety and bioethical issues
(a detailed discussion of bioethical issues can be found in [1]).
Such a possibility is becoming a reality thanks to the merging of
engineering and physics with molecular and cell biology, which
gave rise to synthetic biology. The deﬁning feature of this new dis-
cipline is a striving to apply engineering principles and practices to
molecular and cell biology; these include the principles of abstrac-
tion and standardisation of biological parts, decoupling between
parts to prevent undesired cross-talking, and the application of
quantitative modelling of the synthetic genetic circuits, prior to
their implementation, in order to guide their design.
It is worth brieﬂy considering the relationship between systems
biology and synthetic biology: systems biology can be thought of
as the other side of the coin, in that it aims at developing a formalal Societies. Published by Elsevier
netics and Medicine (TIGEM),
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k.understanding of biological systems through the application of
engineering and physics principles (for a detailed discussion refer
to [2]). Synthetic biology can be used as a tool in systems biology,
by applying the famous Feynman quote ‘‘What I cannot create, I do
not understand’’: that is, in order to understand a naturally occur-
ring biological system, a simpler version of it can be built using
synthetic biology, to identify which are its essential features. Also
the contrary can be true, i.e. principles underlying the functioning
of biological systems identiﬁed by systems biology can be used to
design novel circuits in synthetic biology.
In what follows, we will review the most signiﬁcant develop-
ments achieved so far in synthetic biology, with emphasis on appli-
cations relevant to human health, starting from unicellular
organisms and concluding with early attempts to engineer mam-
malian cells and multicellular organisms. We will also describe
some fascinating, albeit immature, avenues of research in synthetic
biology, such as the application of control engineering to living
organisms, and discuss the challenges lying ahead.
2. Engineering of unicellular organisms for disease prevention,
diagnosis and treatment
Most of the efforts in the ﬁeld of synthetic biology in the last
decade have been devoted to design and develop functional geneB.V. Open access under CC BY-NC-ND license.
F. Menolascina et al. / FEBS Letters 586 (2012) 2122–2128 2123circuits in prokaryotes and unicellular eukaryotes [3]. Starting
from the seminal works describing a ‘‘toggle switch’’ to turn gene
expression off or on [4] to the ‘‘repressilator’’, capable of driving
periodic gene expression [5], engineering of biological systems
has evolved to include circuits of ever increasing complexity,
including logic gates, clocks, counters, and inter-cellular communi-
cation [6,7]. More recently, efforts are underway in creating ‘‘min-
imal organisms’’ by completely replacing their genome with a
synthetic one, rather then adding new synthetic circuits to an
existing genome. The aim is to engineer minimal organisms acting
as ‘‘chassis’’ able to perform new complex functions, encoded in
the synthetic genome, yet unencumbered by functions encoded
in their native genome.
In what follows, we describe some of the recent applications of
synthetic biology relevant to human health, employing engineered
unicellular organisms (refer also to [8] for a thorough review). We
will conclude the section with a brief overview on the on-going ef-
forts to create a ‘‘minimal organism’’.
2.1. Application of synthetic biology to infectious diseases
Infectious disease prevention usually relies on different routes:
host-pathogen interaction inhibition and pathogen neutralization
can be listed among them. Both of these approaches have been
exploited from the standpoint of synthetic biology to tackle highly
aggressive diseases (Fig. 1a). Duan and March investigated the pos-
sibility of using the probioticEscherichia coli (Nissle, 1917) as signal
mediators for inhibiting cholera by hijacking Vibrio cholerae quo-
rum sensing (QS) [9]. QS is used by the pathogen to sense high cell
densities in its population and to inhibit its virulence genes. A
strain of E. coliwas engineered to express the V. cholerae QS autoin-
ducer molecule cholera-autoinducer-1 (CAI-1) (known to preventDisease prevention, diagnosis and treatment
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in expression to the measured ‘‘time course’’ and adjusting the stimuli given to the cellvirulence when present at high concentrations in conjunction with
autoinducer 2 also present in E. coli). This engineered strain was
administered to mice following ingestion of the pathogen V. chol-
erae, resulting in a signiﬁcantly higher survival rate (92%) com-
pared to control mice.
The second route of disease prevention, namely pathogen inhi-
bition, has been explored by Rao et al. [10]. These authors geneti-
cally modiﬁed the same E. coli strain (Nissle, 1917) to secrete HIV-
gp41-hemolysin-A hybrid peptides known to block HIV fusion and
entry into target cells. In this case, the authors were able to dem-
onstrate a signiﬁcant reduction in infected cells as a result of bac-
terial activity.
While these works have been primarily devoted to disease pre-
vention, diagnosis has been one of the most exciting outcomes of
engineered E. coli. In the project ‘‘E. chromi’’, winning the Interna-
tional Genetic Engineering Machine (iGEM) competition in 2009
(University of Cambridge team), E. coli bacteria were engineered
to express different pigments when different compounds were
sensed (thus changing their color). This ‘‘lab-in-a-cell’’ approach
could be a suitable and cost effective way to carry out diagnosis
for a range of human diseases from human derived samples.
In another seminal work [11], the authors provided evidence for
the feasibility and beneﬁts of using engineered enzymatic bacterio-
phage to reduce bacterial bioﬁlms. Bacteriophages were engi-
neered to express a bioﬁlm-degrading enzyme during infection.
This led to the simultaneous attack of bacterial cells in the bioﬁlm
and of the bioﬁlm matrix, which is composed of extracellular poly-
meric substances. This work demonstrated for the ﬁrst time that a
synthetically engineered enzymatic phage substantially reduced
bacterial bioﬁlm cell counts by 4.5 orders of magnitude
(99.997% removal), which was about two orders of magnitude
better than that of the non-enzymatic phage. In a follow up studySynthetic Biology for Systems Biology
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in E. coli with an engineered bacteriophage enhances killing by
quinolones by several orders of magnitude in vitro and signiﬁ-
cantly increases survival of infected mice in vivo.
Genome scale synthetic biology has been recently proposed as a
means to obtain novel vaccines by Coleman et al. [13]; the authors
took advantage of the intrinsic redundancy of the genetic code to
decrease the efﬁciency of protein translation thus severely affect-
ing the ability of the poliovirus virus to infect cells. Mice immu-
nized with this engineered poliovirus were found to be resistant
to wild type poliovirus infection.
2.2. Application of synthetic biology to cancer and other complex
diseases
Other groups pushed the synthetic biology paradigm even fur-
ther and engineered bacterial strains to selectively invade and kill
cancer cells, as shown in Fig. 1a (see [14] for a review). In this
application, rather than using bacteria as a ‘‘lab-in-a-cell’’ to (con-
ditionally) produce therapeutic compounds, bacteria are treated as
‘‘highly programmable smart particles’’ able to (a) target tumours,
(b) produce cytotoxic molecules, (c) self-propel, (d) respond to trig-
gering signals, (e) sense the local environment and (f) produce
externally detectable signals. Some of the most representative
works in this ﬁeld include the contribution by Anderson et al.,
who engineered E. coli to express invasin, a protein from Yersinia
pseudotuburculosis, that allows bacteria to invade tumor cell lines
(such as HepG2 and HeLa) only under speciﬁc conditions (hypoxia,
cell density and external compounds) [15]. Xiang et al. demon-
strated how bacteria can be engineered to express short hairpin
RNA to elicit RNA-interference in mammalian cells [16].
Ganai et al. engineered non-pathogenic Salmonella typhimuri-
um (found to preferentially target tumours over normal tissue)
to secrete murine TNF-related apoptosis-inducing ligand (TRAIL)
causing conditional caspase-3-mediated apoptosis and death of
cancer cells [17].
Royo et al. used Salmonella enterica to engineer an acetyl sali-
cylic acid (ASA) inducible regulatory control circuit with an expres-
sion module encoding the 5-ﬂuorocytosine–converting enzyme
cytosine deaminase. After infecting mice with tumors by exposing
them to engineered bacteria, before 5-ﬂuorocytosine adiministra-
tion, these authors found a signiﬁcant reduction in tumor growth
[18].
Given their generally human-symbiotic behavior, gut commen-
sal bacteria are the obvious choice for human disease treatment:
this is the case of Bacteroides ovatus, used by Farrar et al. to condi-
tionally secrete a biologically active murine interleukin 2 for
immunotherapy purposes [19]. More recently, Duan et al. engi-
neered E. coli Nissle, 1917 strain to express GLP-1 and PDX-1,
two proteins shown to stimulate intestinal epithelial cells to syn-
thesize insulin [20] and thus proposing a treatment for diabetes.
Drug development can strongly beneﬁt from the introduction of
synthetic biology, thanks to its ability to provide new means to
modify an organism to produce a compound of interest [21]
(‘‘lab-in-a-cell’’ paradigm), or to use an organism as a vector to de-
liver the drug only under speciﬁc conditions (‘‘smart particles’’
paradigm).
Drug production by synthetically engineered cells has its most
striking example in the case of artemisinic acid, a precursor of ater-
misinin, the primary antimalarial drug (a very effective yet expen-
sive treatment for this disease). Ro et al. were able to obtain high
titres of artemisinic acid produced by re-engineering the mevalo-
nate pathway within the yeast strain Saccharomyces cerevisiae
[22].2.3. Towards a ‘‘minimal organism’’
Creating a ‘‘minimal organism’’ acting as a living chassis will en-
able engineering of new complex functions in the cell. The para-
digm followed by synthetic biologists is the one used in
computer science, where a computer (the minimal organism) is a
general-purpose machine and it can perform speciﬁc functions
using software (the synthetic genome). A synthetic genome should
retain only a minimal set of wild-type genes and regulatory
sequences that encode for essential functions, thus allowing a
desired set of new genes encoding for complex circuits to be
encoded in the genome.
Different labs are currently using the Mycoplasma pneumoniae
[23,24] or the Mycoplasma mycoides recipient cells [25], due to
their reduced genome size, in order to obtain cells with a minimal
genome, by removing non-essential genes from the host genome.
In the case of M. mycoides, chosen by the Craig Venter Institute
for constructing their ‘‘minimal organism’’, Gibson et al. attracted
the attention of both the scientiﬁc community and the public opin-
ion [25]. As a matter of fact, they demonstrated for the ﬁrst time
that it is possible to ‘‘boot up’’ a bacterial cell by replacing the end-
ogeneous genome with a fully synthetic genome replica assembled
by DNA synthetisers. The next step will be to synthesise a minimal
genome by removing non-essential genes. This contributed to raise
public concerns about potentially harmful consequences of syn-
thetic biology to the point that a Presidential Commission has been
established in US; the results of the work carried out by this
commission is currently accessible through (Presidential Commis-
sion for the Study of Bioethical Issues, 2010 http://www.bioeth-
ics.gov/).
A complementary approach has been proposed for more
complex eukaryotic genomes by developing partially synthetic
genome: a new yeast strain has been engineered by partially
replacing a chromosome arm with a synthetic version of it includ-
ing an inducible evolution system, SCRaMbLE (synthetic chromo-
some rearrangement and modiﬁcation by loxP-mediated
evolution) through which combinatorial mutagenesis can be
induced to lead to yeast strains with a broad variety of phenotypes
[26].
At the present time, no minimal organism has been created yet,
however progress is being made at a fast pace, and applications of
this technology may soon impact biomedical research.
3. From unicellular to multicellular organisms: synthetic
biology for systems biology
Although most of the studies in synthetic biology are related to
prokaryotes and unicellular eukaryotes, the need for innovative ap-
proaches to study and modify complex signalling and regulatory
networks has prompted advances of this ﬁeld also in cells from
multicellular organisms. The ﬁrst applications of synthetic biology
in mammalian cells aimed at adapting synthetic circuits originally
built in bacteria [4,5] by means of well-characterized biological
parts and orthogonal elements isolated from the endogenous cellu-
lar context. Intelligent use of these techniques allowed researchers
to construct ‘‘proof-of-principle’’ toggle switches [27,28] and oscil-
latory networks [29].
Building on this early successes, scientists have then used syn-
thetic biology not only to engineer new functions in the cell, but
also, in the framework of systems biology, to build simpler versions
of endogenous gene regulatory networks to gain knowledge of the
‘‘rules’’ governing their wiring diagram (Fig. 1b). Questions such as
why some transcription factor regulate their own transcription
(positive/negative self-feedback loop), or how the circadian clock
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ﬁed ‘‘synthetic’’ models of these biological processes.
Indeed, over the last few years, the design of simple circuits in
mammalian cells has been used to shed light on the biological
meaning of recurrent motifs and structures observed in gene regu-
latory networks.
3.1. Synthetic switches in mammalian cells
The ﬁrst toggle switch in mammalian cells readapted the basic
topology of the E. coli toggle switch invented by Gardener et al. [4]
and reported in Fig. 1b (PFL). Speciﬁcally, Kramer et al. [28] engi-
neered a switch by assembling two transcription factors (PIP-KRAB
and E-KRAB) mutually inhibiting their expression. Two antibiotics
can be transiently applied to the cells to ‘‘switch’’ the system either
on (PIP-KRAB high, E-KRAB low) or off (PIP-KRAB low, E-KRAB
high) by transiently restricting E-KRAB repression with erythromy-
cin, or PIP-KRAB repression with pristinamycin. The authors
showed that the epigenetic state of the switch can be transmitted
to daughter cells after cell division.
3.2. Synthetic oscillators in mammalian cells
The periodic expression of genes underlies the functionality of
fundamental processes found in every mammalian cell, such as
the circadian clock, and the cell cycle, essential for coordinating
the physiology of the whole organism.
To better understand the rules underlying the periodic expres-
sion of genes, several synthetic circuits have been built and tested
in bacteria, while the stable implementation of a synthetic oscilla-
tor in mammalian cells still remains an open problem. Neverthe-
less, in 2009, the ﬁrst mammalian oscillator was described [29].
The circuit consists of a sense-antisense expression ‘‘pendulum’’
with the tetracycline-dependent transactivator tTA auto-regulat-
ing itself, thereby forming a positive feedback loop (PFL) [29].
The tTA drives also the transcription of the streptogramin-depen-
dent transactivator, which induces the tTA in antisense orientation,
thus reducing the tTA levels (negative feedback loop - NFL). This
PFL + NFL topology (Fig. 1c) gives rise to periodic ﬂuctuation of
tTA levels, which were monitored via a highly unstable form of
GFP, whose expression is driven by the tTA. The different compo-
nents of the genetic oscillator were carried by three different
plasmids. Even considering limitations of a transient transfection
based approach, the oscillator showed spontaneous, self-sustained
oscillations with an average period of 147 min.
3.3. Engineering and analysis of basic networks motifs
Swinburne et al. investigated if and how intron length affects
the timing of gene expression [30]. To this aim, they used a syn-
thetic biology approach to engineer and analyse a simpliﬁed net-
work motif in mammalian cells isolated from endogenous
regulation. Indeed, endogenous intron-containing genes are sub-
jected to multiple transcription and post-transcriptional control,
and therefore are not amenable to study the impact intron lengths
have on their expression.
The authors engineered a negative feedback loop (Fig. 1c)
expressing a humanized Tet repressor (TetR) fused to the fast-
maturing Venus variant of yellow ﬂuorescent protein (YFP) under
the strong beta-actin promoter, including its ﬁrst intron. The TetR
fusion contains a nuclear localization signal thus allowing TetR to
bind the tet-operators (tetO) in its own promoter region and inhi-
bit transcription initiation of its own gene; repression can be
relieved by the addition of doxycycline. By varying the size of the
ﬁrst intron of beta-actin upstream of the reporter gene by inserting
intron cassettes from 1 kb up to 16-kb, the authors showed anincreasing delay in transcription correlated to the intron length.
Moreover, this delayed negative feedback loop induced periodic
pulses of protein expressing, consistently with mathematical mod-
eling of this simple, but dynamically rich, motif. Interestingly, the
delayed NFL is a basic motif also found in the endogenous circadian
clock regulatory network.
In a recent work in our lab [31], we instead investigated the
properties of another common motif: the positive feedback loop
(PFL), as shown in Fig. 1c. To this end, we engineered Chinese
Hamster Ovary (CHO) cells with a cassette composed of the tetra-
cycline-controlled transactivator tTA driven by a CMV-TET pro-
moter containing seven repeats of the Tet Responsive Element
(TRE) bound by the tTA protein itself. The mRNA expressed from
this promoter contains an Intra Ribosomal Entry Sequence (IRES)
in-between the transactivator tTA and a destabilised Yellow Fluo-
rescent Protein (d2EYFP).
The transcriptional activity is restricted by the addition of doxy-
cycline that prevents binding of tTA to the CMV-TET promoter. The
PFL is a typical example of a bistable circuit, which can have two
equilibria (ON or OFF), as in the case of the toggle switch described
earlier.
We demonstrated both experimentally and via mathematical
modeling that another property of the PFL is to greatly slow down
the transcriptional response to an inducer molecule (doxycycline
in our case) compared to control cells, where the PFL is broken
by placing the tTA under the control of a constitutive CMV
promoter.
Hence, the PFL motif exhibits a dynamic behaviour which is
very different from that obtained when auto-regulation is re-
moved, demonstrating that such a behaviour relies on the intrinsic
properties of the network topology.
Interestingly, both NFL and PFL are basic network motifs found
in clock-like mechanisms giving rise to circadian and ultradian
oscillators [32], as well as, in signaling transduction and regulatory
pathways [33].
Another fascinating example of the application of synthetic
biology to elucidate how endogenous signalling transduction path-
ways work, it has been reported by O’Shaughness et al. [34]. The
authors built an exogenous, minimal mammalian MAPK cascade
in yeast to investigate its behaviour in an insulated setting, thus
preventing the challenges due to the interconnectivities present
in the endogenous environment. The authors show, both experi-
mentally and via mathematical modelling, that varying the relative
concentrations of MEK and ERK confers great ﬂexibility and can in-
duce either low or high ultrasensitivity response. They further
investigated the effect of scaffolding proteins on the signalling
pathway response.
4. Engineering in multicellular organisms relevant to human
health: from genetic engineering to synthetic biology
The complexity of multicellular organisms makes the applica-
tion of synthetic biology seem like a daunting task. The idea of
engineering a complete synthetic genome even for the simplest
of these organisms is still far-fetched. Nevertheless, when consid-
ering the engineering of small synthetic circuits to obtain a desired
phenotype, some preliminary results have already been reported,
as brieﬂy detailed in the following sections and in Fig. 1c.
4.1. Engineering multicellular organisms: An engineered mosquito to
control the dengue disease
Harris et al. have recently reported data from the ﬁrst open-
ﬁeld trial in which engineered mosquitoes were released in a site
on Grand Cayman [35]. This study targets the predominant
mosquito vector, Aedes aegypti. This novel approach overcomes
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(SIT) that was unable to control dengue spreading, since the radia-
tion-mediated sterilization of the mosquitoes made them incapa-
ble to compete with wild-type males for mating. The system
proposed is based on the RIDL technique (Release of Insects carry-
ing a Dominant Lethal genetic system) [35]. A. aegypti mosquitoes
were engineered with a simple Positive Feedback Loop containing
the tTA protein self-activating its own promoter and causing a
highly penetrant, dominant, late-acting lethality in progeny, prob-
ably due to the site-speciﬁc integration of the construct [35]. Males
were reared to maturity through the use of tetracycline in the lab-
oratory, which prevents tTA protein from bind its own promoter,
and then were released in the ﬁeld. The analysis of progenies
followed for a four-week period proved that the engineered mos-
quitoes were able to compete for mates, and that the method is
feasible to control dengue through suppression of populations of
A. aegypti.
Due to the efﬁciency of this approach, this application has been
hailed as a success of synthetic biology; however, it could also be
classiﬁed as ‘‘genetic engineering’’, due to the lack of quantitative
modelling guiding the circuit design prior to its implementation.
Indeed, a classic genetic engineering approach was possible since
the circuit was very simple (i.e. a positive feedback loop), and
the late lethality phenotype was obtained by screening colonies,
without identifying the exact mechanism [36].
4.2. A synthetic network to control urate homeostasis in mice
Kemmer and collegues described the development and valida-
tion in urate-deﬁcient mice, of a simple synthetic circuit able to
sense and maintain constant uric acid levels in the bloodstream
making use of control engineering principles [37]. The synthetic
circuit is composed by the bacterial transcriptional repressor HucR,
optimized for mammalian cells, which binds the SV40 promoter,
engineered to contain eight cognate hucO operator sequences
(Psv40-hucO), in absence of uric acid. High urate levels induce
the de-repression of the promoter that, in turn, triggers the expres-
sion of a secretion-engineered Aspergillus ﬂavus urate oxidase that
eliminates uric acid. The transplantation of microencapsulated
cells stably expressing the circuit, in urate oxidase deﬁcient mice
with high urate levels, shows that the device is able to discriminate
between mice developing hyperuricemia and mice with low urate
levels, fostering the possibility to use this device in a therapeutic
approach (Fig. 1d).
Also in this case the circuit was very simple, consisting of an
inducible promoter expressing a therapeutic enzyme, however in
this case a quantitative model was used to guide the circuit design
[37].
4.3. The next frontier: controlling biological systems
A new ﬁeld of research has been recently established at bound-
ary between synthetic biology and control engineering (Fig. 1d).
Control engineering is a well-established engineering discipline,
which aims at forcing a physical system to attain a desired behav-
iour by appropriately modulating ‘‘input’’ signals to which the sys-
tem is known to respond. Control engineering principles can be
used to elucidate how cells and organisms control and ﬁne tune
the activity of key pathways in face of ﬂuctuations [38]. In addition,
control engineering can be used in conjunction with synthetic
biology to regulate at will the dynamics of gene expression or
signalling pathways in a cell, opening up a new set of tools for
research in systems biology and for biomedical applications.
A great analogy to better understand how a control system
works has been presented by Allinson et al. and reported here
[38]: the indoor temperature in a house is detected by a thermostat,which then regulates the heat ﬂow to achieve a set, desired temper-
ature. The thermostat operates via a negative feedback loop, where
the desired temperature is compared to the measured temperature
and based on their difference (i.e. the error), a control system deci-
des whether to switch on or off the heat generator.
In what follows, we present some of the most recent examples
of applications of control engineering principles in conjunction
with synthetic biology.
4.4. Controlling gene expression in living cells
Inducible expression systems able to switch on or off the
expression of a gene/microRNA of interest have revolutionarised
molecular biology, greatly simplifying and expanding the experi-
mental tools available to probe gene function. However, these sys-
tems suffer from an intrinsic limitation, i.e. the expression level can
be chosen to be either be high or low, but the experimenter has no
control on the exact level of expression of the gene, neither on its
expression dynamics.
Coupling control engineering to synthetic biology allows for the
ﬁrst time in the history of molecular biology to precisely control
the amount and the time-course of gene expression, or protein
activation, in living cells (Fig. 1d).
Uhlendorf et al. [39] proposed a ﬁrst step towards in vivo con-
trol of protein localisation in real-time, by combining a microﬂu-
idic device, an epi-ﬂuorescence microscope and software
implementing control approaches. They used the Hyper Osmolar
Glycerol (HOG) pathway in the yeast S. cerevisiae, which senses
osmolarity and triggers osmotic stress responses to maintain water
homeostasis via translocation of the effector protein Hog1 to the
nucleus. The authors show that they can precisely control the
localisation and concentration of Hog1 protein in the nucleus via
a feedback control system. The controller changes in real-time
the osmalirity level sensed by yeast cells growing in the microﬂui-
dics device, by monitoring the concentration of a tagged Hog1 in
the nucleus via the microscope.
We described a feedback control system able to regulate at will
the expression of a gene of interest embedded in a complex net-
work in yeast by automatically changing the concentration of an
inducer molecule in the growing medium [40]. Speciﬁcally, we de-
signed a microﬂuidics platform to grow yeast cells and to change at
will, in real-time, the concentration of galactose or glucose in the
growing medium. This change in carbon source indirectly affects
the level of expression of a ﬂuorescent protein in a complex gene
regulatory network [41]. The ﬂuorescence level is monitored by a
computer connected to a ﬂuorescence microscope that automati-
cally administers galactose or glucose to the cells to achieve the
desired expression level and/or expression dynamics.
Milias-Argeitis et al. proposed a strategy to control, at the pop-
ulation level, the expression of a ﬂuorescence protein using an
opto-genetic approach [42]. The authors use the light-responsive
Phy/PIF module to control the level of a PIF3 protein fused to the
Gal4 activation domain. By applying pulses of light, they are able
to regulate the level of a YFP reporter driven by the Gal1 promoter,
which contains Gal4 binding sites. In this case, ﬂuorescent levels
were measured via FACS (Fluorescence Activated Cell Sorter).
4.5. Controlling signaling pathways
Toettcher et al. used principles of control engineering to auto-
matically control the amount of light needed to ﬁne tune the intra-
cellular activation of a signalling pathway using genetically
encoded light-gated proteins [43]. Also this system relies on the
Phy-PIF opto-genetic system. The user provides a desired (time-
varying) amount of PIF-BFP ﬂuorescent fusion protein to be local-
ised to the plasma membrane, the controller then compares it to
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determines the appropriate light input to provide to the cell. Using
this strategy, the authors succeeded in achieving desired (time-
varying) levels of membrane recruitment of PIF-tagged proteins
within seconds.
Application of this technology will allow to derive precise quan-
titative models of signaling pathways and to study their activation
dynamics in unprecedented details, opening up a whole array of
innovative experiments.
5. Conclusions
In this review we have ﬁrst shown examples of state-of-the-art
applications of synthetic biology to engineer unicellular organisms
towards disease diagnosis, treatment and prevention. Bacteria can
be engineered to function as a ‘‘lab-in-a-cell’’ to produce pharma-
cologically active compounds, as sensors to measure the presence
of a diagnostic marker, or modiﬁed to work as ‘‘smart particles’’
able to recognise and kill cancer cells. Although many of these
applications are only ‘‘proof-of-concepts’’ some may reach practi-
cal applications very soon.
There are still, however, a few challenges lying ahead: (a) up-
scaling the modelling and construction of synthetic circuits is still
very difﬁcult due to a lack of standardisation of biological parts
associated to quantitative descriptive parameters and to cross-
talking between the different parts. Effective means to decouple
the different biological parts (equivalent to operational ampliﬁes
in electronics) in order to reduce cross-talking have not been found
yet [44,45]. These problems will be mitigated if efforts in creating a
minimal organism with a minimal genome will succeed, since it
will be easier to engineer orthogonal parts that do not interact with
the endogenous components [46]; (b) new experimental tech-
niques are needed for fast ‘‘prototyping’’ of synthetic circuits, such
as DNA synthesisers capable of generating long sequences at
affordable costs, and innovative modular cloning techniques,
which allow to quickly ‘‘mix and match’’ different biological parts
[25]; (c) evolution in synthetic biology of unicellular organisms can
be used as a tool [46], but it can also be a curse; indeed, if the
organism is not properly engineered, evolution will eradicate any
modiﬁcation which decreases the ﬁtness of the individual cells.
Similar considerations apply to synthetic biology in multicellu-
lar organisms, with the added difﬁculty of engineering cell-to-cell
signalling, essential for properly inducing a desired tissue/organ-
ism-level phenotype. Quantitative understanding of cell signalling
is essential for proper engineering, and although this has not been
yet achieved, progress is being made at a rapid pace [47,48]. Mod-
elling becomes possible if there are biological parts with quantita-
tive parameters available, and it becomes essential for up-scaling,
when synthetic circuits with more than a few parts need to be
built. Because of these limitations, we are still in the very early
stages of synthetic biology in multicellular organisms. However,
techniques such as using engineered encapsulated cells could be
a reliable approach to bring synthetic biology approaches to the
clinic in a reasonable time [37] (Fig. 1c).
We also reviewed some of the recent developments in the
application of control engineering to living organisms. Control
engineering offers unprecedented opportunities in the ﬁelds of sys-
tems and synthetic biology that span from performing highly infor-
mative experiments to investigate single cell behavior to turning
this knowledge into therapeutic strategies meant to revert patho-
logical states.
Despite the technical and methodological challenges still open,
engineering and control of biological systems will likely yield new
‘‘synthetic micro-organisms’’ able to sense ‘‘molecular markers’’ of
a disease and perform a therapeutic action in response; orautologous transplants of engineered human cells to restore
homeostasis of dysregulated pathways in disease.
The drive in merging engineering and biology has begun and
shows no sign of slowing down.
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